Zahid Bashir MB BS, MSc joins as Chief Medical Officer, bringing significant clinical haematology and oncology experience, having led the development and launch of innovative medicines including Kite Pharma’s first CAR-T clinical trial Richard Rutter, PhD joins as Head of Biology, with a track record of progressing drugs from inception to the clinic, he brings […]
https://myricxpharma.com/wp/wp-content/uploads/2020/05/logo_Mryicx.svg00proteinbarhttps://myricxpharma.com/wp/wp-content/uploads/2020/05/logo_Mryicx.svgproteinbar2022-02-22 08:52:452022-02-22 15:11:08Myricx Pharma Announces Senior Team Expansion with Appointment of CMO, and Heads of Biology and Bioinformatics
Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]
https://myricxpharma.com/wp/wp-content/uploads/2020/05/logo_Mryicx.svg00proteinbarhttps://myricxpharma.com/wp/wp-content/uploads/2020/05/logo_Mryicx.svgproteinbar2020-11-16 07:49:432022-02-22 08:53:27Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Myricx Pharma Announces Senior Team Expansion with Appointment of CMO, and Heads of Biology and Bioinformatics
Zahid Bashir MB BS, MSc joins as Chief Medical Officer, bringing significant clinical haematology and oncology experience, having led the development and launch of innovative medicines including Kite Pharma’s first CAR-T clinical trial Richard Rutter, PhD joins as Head of Biology, with a track record of progressing drugs from inception to the clinic, he brings […]
Myricx Pharma Announces Board and Executive Appointments
Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director Robin Carr, PhD steps up to CSO from his previous position as CDO Stevenage, UK, April 20 2021 […]
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners Led by a team of world-class scientists […]